U.S. President Donald Trump makes an announcement from the Oval Workplace on the White Home in Washington, D.C., U.S. Nov. 6, 2025.
Jonathan Ernst | Reuters
President Donald Trump on Thursday is slated to announce the launch of TrumpRx – a direct-to-consumer web site that’s key to his administration’s efforts to decrease prescription drug prices within the U.S.
In a put up on X, White Home press secretary Karoline Leavitt stated Trump and different administration officers will debut the brand new web site at 7 p.m. ET on Thursday.
She stated hundreds of thousands of Individuals would lower your expenses by means of TrumpRx, however it’s nonetheless unclear if all sufferers – notably these with insurance coverage protection – will see extra value financial savings from utilizing that website to purchase their medicines. TrumpRx targets people who find themselves keen to pay with money and forgo insurance coverage, which suggests that folks with or without restricted protection could profit probably the most.
The location isn’t anticipated to promote medicine on to American sufferers, however will act as a central hub that factors them to drugmakers which are providing reductions on sure merchandise on their very own direct-to-consumer websites. For instance, Eli Lilly and Novo Nordisk have supplied their blockbuster weight problems medicine at hefty reductions to cash-paying sufferers.
In latest months, each firms and not less than 14 different drugmakers have negotiated agreements with the Trump administration to take part on the platform and voluntarily promote sure medicines at a reduction to Medicaid sufferers. These landmark offers are a part of Trump’s broader “most favored nation” coverage, which pushes to hyperlink U.S. drug costs to the bottom ones overseas.
It’s the authorities’s newest effort to attempt to rein in U.S. prescription drug costs, that are two to 3 instances larger on common than these in different developed nations – and as much as 10 instances greater than in sure international locations, based on the Rand Corp., a public coverage assume tank.
In an unique interview with CNBC final week, Eli Lilly CEO Dave Ricks stated the corporate was the primary drugmaker to promote weight problems remedies on to sufferers, and that TrumpRx is “taking that and increasing it throughout the business” to different medicines.
“We’re all for that,” Ricks stated.
Questions on financial savings
Questions stay about how a lot financial savings folks can anticipate in the event that they use TrumpRx to purchase their medicines.
The introduced value reductions for sure medicine are framed as steep cuts from their so-called retail listing costs. For instance, below Novo Nordisk’s settlement with the administration, its diabetes drug Ozempic will probably be priced at $350 monthly on TrumpRx, which is lower than half of its roughly $1,000 month-to-month listing value.
However these listing costs are sometimes far larger than what non-public insurers and authorities packages finally pay for medicines after rebates, reductions and different concessions, based on researchers at Georgetown’s Medicare Coverage Initiative. That implies some payers could already be securing costs akin to — or decrease than — the newly introduced reductions on drugs below the Trump offers.
The researchers cited one examine that discovered that common reductions on brand-name medicine in Medicare Half D run round 40% of listing costs. In the meantime, reductions in Medicaid exceed 75%, in accordance to a Congressional Finances Workplace examine.
Medicine on TrumpRx
The administration has not supplied a full listing of medicine that will probably be listed on TrumpRx.
However out there data from latest drug pricing offers signifies many extensively used medicine will probably be supplied on the location at a reduction:
- Ozempic injection for diabetes, made by Novo Nordisk: $350 monthly, down from round $1,000
- Wegovy injection for weight problems, made by Novo Nordisk: $350 monthly, down from round $1,350
- Wegovy tablet for weight problems, made by Novo Nordisk: $150 monthly for the beginning doses
- Zepbound injection for weight problems, made by Eli Lilly: $350 monthly, down from $1,086
- Trulicity for diabetes, made by Eli Lilly: $389 monthly, down from about $1,000
- Emgality for migraines, made by Eli Lilly: $299, down from round $764
- Repatha for decreasing ldl cholesterol, made by Amgen: $239, down from $573
- Reyataz for HIV, made by Bristol Myers Squibb: $217, down from $1,449
- Januvia for diabetes, made by Merck: $100, down from $330
- Epclusa for Hepatitis C, made by Gilead: $2,425, down from $24,920
- Jentadueto for diabetes, made by Boehringer Ingelheim: $55, down from $525
- Xofluza for flu, made by Genentech: $50, down from $168
- Advair Diskus inhaler 500/50, made by GSK: $89, down from $265
- Mayzent for a number of sclerosis, made by Novartis: $1,137, down from $9,987
- Plavix, made by Sanofi: $16, down from $756
In an interview with CNBC at a convention in January, Bristol Myers Squibb CEO Chris Boerner stated the corporate has a number of merchandise on its present direct-to-consumer platform, which first supplied a cash-pay low cost on its blood thinner Eliquis. That platform will hyperlink to TrumpRx, he stated.
The corporate goes to look at methods to place extra merchandise in its portfolio by itself platform, “the place it is smart,” Boerner added. He stated Bristol Myers is “aligned with the administration” on the difficulty of the U.S. healthcare system being too complicated, and stated a number of middlemen can enhance prices.
“What we like about these [direct-to-consumer models], the place they make sense from a enterprise standpoint, is you are capable of circumvent a few of that,” Boerner stated.
